Defiance Connective Technologies ETF (NASDAQ: SIXG)

Últimas noticias sobre Defiance Connective Technologies ETF (NASDAQ:SIXG)

Defiance Connective Technologies ETF

Technology

Communication Services

Real Estate

The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index. The Index is a rules-based index that consists of a tiered, modified market capitalization-weighted portfolio of the U.S.-listed equity securities, including depositary receipts, of companies whose products or services are predominantly tied to the development of 5G networking and communication technologies (collectively, 5G Companies).

Apple Inc

NVIDIA Corporation

Broadcom Corp - Common Cl A

Oracle Corp.

Ocisco Systems, Inc

Qualcomm Inc.

Advanced Micro Devices Inc.

Analog Devices, Inc.

Arista Networks Inc.

Nxp Semiconductors N V

Celestica, Inc.

Credo Technology Group Holding Ltd

Marvell Technology Inc

Kyndryl Hldgs Inc

Nokia Corp-spon ADR

Datadog Inc

Telefonaktiebolaget Lm Ericsson ADR

Sixt SE

News

PERI

Perion Network Announced First Quarter Preliminary Revenue Of ~$88M (Vs. Cons. Of 83.7M), Adjusted EBITDA Of ~$1.5M And Adjusted EBITDA To Contribution Ex-tac Of ~4%

MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy,&nbsp;a type of nerve damage that can occur <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in diabetes patients</a>.&nbsp;
In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">dose of Streptozotocin (STZ)</a>.
Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity.
<ul>
<li>These results build upon prior preclinical studies using other neuropathy animal models, where orally administered Ketamir-2 outperformed FDA-approved neuropathic pain medications such as pregabalin and gabapentin, demonstrating a favorable safety profile.</li>
<li>Unlike traditional ketamine, Ketamir-2 does not induce dissociative or psychedelic effects and is not a substrate for P-glycoprotein, allowing for more efficient penetration across the blood-brain barrier.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44299076/exclusive-mira-pharmaceuticals-expands-pipeline-enhances-value-proposition-with-development-of-topical-formulation-for-lead-pain-treatment-candidate" rel="noreferrer noopener">EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate</a>
Diabetic neuropathy affects between 28% to 55% of patients with diabetes.
Current treatment options are limited, with first-line therapies such as pregabalin, gabapentin, and duloxetine often delivering only modest symptom relief. These drugs are frequently associated with side effects such as dizziness, fatigue, cognitive impairment, and gastrointestinal discomfort. Up to 50% of patients fail to achieve meaningful pain reduction.
At the same time, the demand for non-opioid therapies is growing rapidly, driven by the ongoing opioid crisis and heightened regulatory scrutiny. Ketamir-2's non-addictive profile and lack of dissociative side effects position it as a strong candidate in this emerging treatment landscape.
MIRA anticipates initiating its Phase 2a trial in diabetic neuropathy by the end of 2025, with the first human efficacy data expected in the first half of 2026.
In parallel, the company is developing a topical slow-release formulation of Ketamir-2 to provide localized pain relief with minimized systemic exposure.
In addition, MIRA is actively conducting ongoing studies assessing the efficacy of Ketamir-2 in models of post-traumatic stress disorder.
In March, MIRA Pharmaceuticals&nbsp;signed a binding letter of intent to acquire&nbsp;SKNY Pharmaceuticals, Inc.
The transaction includes a $5 million capital infusion of cash or equivalent consideration into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44454746/exclusive-mira-pharmaceuticals-signs-to-acquire-skny-pharmaceuticals-expand-pipeline-into-weight-loss-and-smoking-cessation-drug" rel="noreferrer noopener">loss and smoking cessation</a>.
Price Action: MIRA stock closed at $0.89 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44828811/intel-growth-challenges-are-not-over-despite-altera-stake-sale-analyst" target="_blank" rel="noreferrer noopener">Intel Growth Challenges Are Not Over Despite Altera Stake Sale: Analyst</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

MIRA

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

WIIM

NVDA

NVIDIA shares are moving lower after the company said it was recently informed by the US government that it will need a license to export chips to China.

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal'

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Announces Results For Ketamir-2 In Diabetic Neuropathy Animal Model, Says Reinforcing Confidence Ahead Of Phase I Completion

SYDNEY, April 16, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (together with its subsidiaries, "IREN"), today provided an update on its Bitcoin mining expansion.
"We're proud to have reached 40 EH/s, marking yet another significant step toward our 50 EH/s target," said Daniel Roberts, IREN Co-Founder and Co-CEO.
"The site team's rapid expansion of data center capacity at Childress coupled with our best-in-class fleet efficiency and low electricity costs has positioned IREN as one of the largest scale, lowest-cost producers of Bitcoin. We expect to maintain this momentum as we continue to scale mining capacity towards 50 EH/s over the coming months."
IREN has increased its installed self-mining capacity from 37 EH/s to 40 EH/s (15 J/TH efficiency), following the commissioning of additional mining hardware within its Childress Phase 4 (150MW) data centers.
The Company remains well-positioned to achieve 50 EH/s in H1 2025.

IREN

IREN Increases Installed Self-Mining Capacity From 37 EH/S To 40 EH/S; Co. Remains Well-Positioned To Achieve 50 EH/S In H1 2025

Chardan Capital analyst Keay Nakae initiates coverage on Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy rating and announces Price Target of $25.

Price Target

Initiation

Analyst Ratings

KRRO

Chardan Capital Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $25

Management

MDGL

Madrigal Pharmaceuticals' Founder Rebecca Taub, To Transition To Senior Scientific and Medical Advisor; David Soergel, Appointed Chief Medical Officer

NOTE

FiscalNote Holdings Announces The Latest Enhancement To Its Flagship Policy Monitoring Product, PolicyNote, With The Launch Of A Dedicated Tariff Tracker Available Within User Dashboards

K2 Cyber Announces Today Its Partnership With TransUnion For Commercial Cyber Services And Cyber Claims Management

Treasury Secretary Scott Bessent has said that China couldn&#8217;t sell U.S. Treasuries to destabilize the financial markets, as it would affect their economy by weakening their currency.
What Happened: <a href="https://www.benzinga.com/government/regulations/25/04/44812727/bessent-says-tariffs-on-china-are-far-from-a-joke-dismisses-treasury-dumping-fears">Bessent</a>, while speaking to Yahoo Finance, reiterated that there was no purpose for China to &#8220;weaponize&#8221; the U.S. Treasuries, as such a move could affect China&#8217;s own economy.
&#8220;If they started selling Treasuries, they&#8217;d have an effect on the price. But more importantly, they accumulate dollars, and what are they gonna do with the dollars?&#8221; asked Bessent.
&#8220;So if they sell Treasuries, then they would have to sell RMB, and it would strengthen their currency, and they&#8217;ve been doing just the opposite. They&#8217;ve had a weak RMB or Yuan policy. So, it really serves no purpose for them to weaponize Treasuries.&#8221;
China is an export-oriented economy that manufactures many goods and services on its soil. The export-oriented economies generally benefit from a weaker currency. A weaker currency makes a country&#8217;s exports more competitive in the global market by making them cheaper for foreign buyers. This can lead to increased demand for exports, potentially boosting economic growth and creating jobs.
When asked if China still decides to sell U.S. Treasuries regardless of the effect on their currency, Bessent reiterated confidence in the government and the Federal Reserve&#8217;s ability to handle the situation.
&#8220;We have a big toolkit, we do buybacks, and the Federal Reserve has Treasuries at a certain level. If the Federal Reserve believed that a foreign rival were weaponizing the U.S. government bond market or attempting to destabilize it for political gains, I am sure that we would do something in conjunction with each other, but we just haven&#8217;t seen that,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"It really serves no purpose for them to weaponize Treasuries," US Secretary of the Treasury Scott Bessent says on potential fears of Chinese economic retaliation. <a href="https://t.co/5tY8Knuie6">pic.twitter.com/5tY8Knuie6</a>
&mdash; Yahoo Finance (@YahooFinance) <a href="https://twitter.com/YahooFinance/status/1912240941517119801?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">Trump Administration Imposes Up To 245% Tariff On Chinese Imports Amid Intensifying Trade Battle</a>
Why It Matters: Many analysts believed that a &#8220;Trump put,&#8221; from last week to pause the trade implementation for 90 days, was caused by the turbulence in the bond markets.
Schwab&#8217;s Chief Fixed Income Strategist, Kathy Jones, highlighted the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44808935/charles-schwab-tells-investors-to-prioritize-low-volatility-high-quality-investment">divergence between the U.S. dollar and interest rates</a>, confirming foreign selling of Treasuries.
"The dollar fell sharply while yields rose sharply. That does suggest foreign selling was a factor. But it also smacks of a loss of confidence in the United States as a perceived safe haven, which isn't good for the world's reserve currency. This is the type of action you see in emerging markets when volatility hits," said Jones.
While President Donald Trump said in a Truth Social post that he paused the tariffs owing to the negotiation attempts by 75 countries, many analysts believed otherwise.
&#8220;In the end, Trump's stunning about face on tariffs was driven by chaos in the bond market including soaring 10yr and 30yr treasury yields," said Gary Black, the managing partner, the Future Fund LLC.
Ed Yardeni from Yardeni Research said, &#8220;Bond vigilantes hit another homerun.&#8221; Whereas, economist Craig Shapiro said, &#8220;China, just by threatening to sell USTs, basically blew up the bond market and forced the admin to backtrack.&#8221;
In the most recent action, the U.S. increased tariffs on <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">China by 245%</a> on late Tuesday.
Price Action: The Dow closed Tuesday 10.44% below its 52-week peak of 45,073.63. The S&amp;P 500 ended 12.21% off its 6,147.43 high, and the Nasdaq 100 was 15.27% below its 22,222.61 record.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Wednesday. The SPY was down 0.77% to $533.47, while the QQQ declined 1.43% to $451.42, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump" target="_blank" rel="noreferrer noopener">Cathie Wood Says ‘Shock Therapy' From Trump's Trade Moves May End Prolonged Economic Slump</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Government

Politics

Treasuries

Economics

Federal Reserve

Markets

Scott Bessent Says China Won't 'Weaponize' US Treasuries, Citing Risk To RMB And Exports: 'We Do Buybacks'

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Easterly Government Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Easterly Government Properties will release its first quarter financial results on April 29. The company's stock fell around 23% over the past month and has a 52-week low of $7.79.</li>
<li>RSI Value: 23.8</li>
<li>DEA Price Action: Shares of Easterly Government Properties fell 0.8% to close at $8.30 on Tuesday.</li>
<li>Edge Stock Ratings: 18.64 Momentum score with Value at 59.92.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/DEA"><img loading="lazy" decoding="async" width="481" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061358/image-122.png" alt="" class="wp-image-873898" style="width:384px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061358/image-122.png 481w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061358/image-122-300x117.png 300w" sizes="(max-width: 481px) 100vw, 481px" /></a></figure>
<h3 class="wp-block-heading">Summit Hotel Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Summit Hotel Properties will report financial results for the first quarter on Wednesday, April 30, after the market closes. The company's stock fell around 32% over the past month and<a href="https://www.benzinga.com/quote/INN"> has a 52-week low</a> of $3.57.</li>
<li>RSI Value: 24.6</li>
<li>INN Price Action: Shares of Summit Hotel Properties fell 1.8% to close at $3.94 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416">trend in INN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416"><img loading="lazy" decoding="async" width="910" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061455/image-123.png" alt="" class="wp-image-873900" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061455/image-123.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061455/image-123-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061455/image-123-768x711.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>)</h3>
<ul>
<li>LXP Industrial Trust  will release its first quarter financial results before the opening bell on Thursday, May 1. The company's stock fell around 16% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LXP">low of $6.85</a>.</li>
<li>RSI Value: 28.4</li>
<li>LXP Price Action: Shares of LXP Industrial Trust gained 0.1% to close at $7.69 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416">LXP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416"><img loading="lazy" decoding="async" width="877" height="430" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061549/image-124.png" alt="" class="wp-image-873901" style="width:522px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061549/image-124.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061549/image-124-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16061549/image-124-768x377.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Trading Ideas

Top 3 Real Estate Stocks That May Explode In Q2

MAIN

Main Street Estimates Q1 Preliminary Net Investment Income (NII) Of $1.00-$1.02 Per Share And Distributable Net Investment Income Of $1.06-$1.08 Per Share

IonQ and Intellian Technologies, Inc. partner to transform satellite communications with quantum computing
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing and networking industries, announced that it has signed a memorandum of understanding (MoU) with Intellian Technologies, Inc., a leading global provider of satellite communication antennas and ground gateway solutions, to explore how secure quantum networking can transform satellite communications. This memorandum furthers IonQ's work in strategically partnering across South Korea's enterprise, government, and academic sectors and launching initiatives seeking to advance their quantum economy.

IONQ

IonQ Signs MoU With Intellian Technologies To Transform Satellite Communications With Quantum Computing

D. Boral Capital analyst Jesse Sobelson maintains Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) with a Buy and maintains $5 price target.

PAPL

D. Boral Capital Maintains Buy on Pineapple Financial, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and maintains $38 price target.

Reiteration

LENZ

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

Jersey Central Power & Light Company, A Subsidiary Of FirstEnergy, Announced An Offer To Exchange Up To $700M Aggregate Principal Amount Of Its Outstanding 5.100% Senior Notes Due 2035 For An Equal Amount Of 5.100% Senior Notes Due 2035

OPRA

Opera Is Adding Its Browser AI, Aria, To Opera Mini, The Android-based Browser With Over 100M Users Worldwide

President Donald Trump&#8217;s tariff policies, which have sent <a href="https://www.benzinga.com/news/25/04/44779286/trumps-tariff-pause-stirs-markets-goldman-sachs-reverses-recession-call-and-more-this-week-in-economy">global markets reeling</a> over the past few weeks, are rooted in his dislike of the U.S. trade deficit.
While his wide-ranging tariffs ignited backlash from economists, the underlying concern isn't new. In 2003, for Fortune Magazine, billionaire investor and CEO of Berkshire Hathaway Inc. (NYSE: <a href="https://www.benzinga.com/stock/brk-a#NYSE" target="_blank" rel="noreferrer noopener">BRK-A</a>) (NYSE: <a href="https://www.benzinga.com/stock/brk-b#NYSE" target="_blank" rel="noreferrer noopener">BRK-B</a>) Warren Buffett offered a novel solution to tackle the country's trade deficit—one that contrasts sharply with Trump's approach.
What Happened: In <a href="https://fortune.com/2016/04/29/warren-buffett-foreign-trade/">the</a> 2003 article, Buffett used the fictional nations of &#8220;Thriftville&#8221; and &#8220;Squanderville,&#8221; to illustrate how trade deficits lead to growing foreign ownership of domestic assets and increasing debt obligations.
Over time, he feared, this dynamic could weaken the country's financial standing and damage its economic independence.
See Also: <a href="https://www.benzinga.com/25/04/44831422/donald-trumps-145-tariffs-on-china-could-disrupt-teslas-cybercab-semi-production-report">Donald Trump&#8217;s 145% Tariffs On China Could Disrupt Tesla&#8217;s Cybercab, Semi Production: Report</a>
Why It Matters: According to the Bureau of Economic Analysis, the U.S. trade deficit stood at 3.1% of GDP in 2024. Buffett's proposed solution was a market-based fixed system he called the "Import Certificate" system.
Unlike traditional tariffs, it would set up a self-regulating mechanism by compelling importers to buy certificates from exporters, thereby incentivizing exports and discouraging excessive imports.
Though he called it "a tariff called by another name," Buffett emphasised that his suggestion avoided political favoritism and <a href="https://www.benzinga.com/25/04/44832771/the-ball-is-in-chinas-court-trump-says-as-white-house-awaits-beijings-call-china-needs-to-make-a-deal-with-us">worldwide retaliation</a>.
With <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">China now facing up to 245% tariffs</a> on specific products as per the latest update from the White House, perhaps it would be worth revisiting Buffett's proposal to de-escalate the ongoing trade war.
Read Next: <a href="https://www.benzinga.com/markets/25/04/44789113/trumps-trade-war-may-lead-to-gops-massive-downfall-in-2026-warn-republican-senators">Trump&#8217;s Trade War May Lead To GOP&#8217;s Massive Downfall In 2026, Warn Republican Senators</a>
Image via Shutterstock

Financial Advisors

Education

Warren Buffett's 2003 Plan To Fix The Trade Deficit Without A War Deserves A Second Look As US-China Tariff War Continues

CGEM

Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial of CLN-978 In Patients With Rheumatoid Arthritis

Press Releases

Defiance Announces Name and Ticker Symbol Change for FIVG to SIXG - Defiance Connective Technologies ETF

Defiance ETFs Announces Transition of QTUM and SIXG from NYSE Arca to Nasdaq

FIVG

QTUM

SIXG

Comments

Defiance Connective Technologies ETF

Noticias

Últimas noticias sobre Defiance Connective Technologies ETF (NASDAQ:SIXG)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL